Tandem Diabetes at Jefferies: Expanding Market Horizons

During the Jefferies Global Healthcare Conference 2025, Tandem Diabetes Care (TNDM) outlined its strategy focusing on integrated technology and market expansion, particularly in Type 2 diabetes and pharmacy channels. The company aims for a 60% gross margin by the end of 2026, driven by new products like Mobi, which has boosted new pump starts and MDI user conversions, and efficiency gains. Tandem plans to expand direct operations in select European markets starting in 2026 and anticipates double-digit revenue growth through increased market penetration, though macroeconomic uncertainties remain a potential challenge.

Analysis

Tandem Diabetes Care (TNDM) outlined a robust growth strategy at the Jefferies Global Healthcare Conference, emphasizing technological innovation, market expansion, and significant margin improvement targets. The company is targeting a 60% gross margin by the end of 2026, with a long-term goal of 65%, largely driven by its new Mobi pump, which has already spurred double-digit growth in new pump starts from MDI users for four consecutive quarters and increased new prescribers. Tandem reported record Q1 revenue and is aggressively pursuing the Type 2 diabetes market, which more than doubles its addressable market, aiming to increase penetration from 5% to potentially 25%. A key strategic pillar is the expansion into the pharmacy channel, where Mobi currently has approximately 30% of US lives covered under agreements; management believes this channel is underappreciated and pivotal for margin uplift and patient accessibility, though broad coverage is anticipated to take 3-5 years. Furthermore, Tandem plans to establish direct operations in select European markets starting 2026 to capture margin and accelerate growth in currently underpenetrated OUS markets. Despite a strong Q1 performance, the company maintained its full-year guidance, citing potential macroeconomic uncertainties, but remains focused on achieving double-digit revenue growth through its evolving product portfolio, including an upcoming Android version for Mobi, Abbott Libre 3 integration, and the future Sigi pump, alongside a nearly completed US sales force expansion.

Key Decisions for Investors

• Investors should monitor Tandem's execution on its multi-pronged growth strategy, particularly Mobi's continued traction and contribution to new MDI user conversions, alongside progress in the significantly expanded Type 2 diabetes market and the critical expansion within the pharmacy channel, which management views as key to achieving its targeted 60% gross margin by the end of 2026.
• Consider the company's innovation pipeline cadence, including the upcoming Sigi pump and important CGM integrations like Abbott's Libre 3, as crucial for maintaining competitive advantages and driving market penetration, while also tracking the financial impact of direct European operations commencing in 2026 and the productivity ramp-up of the expanded US sales force.
• Evaluate the balance between Tandem's optimistic outlook, supported by strong Q1 results and positive product momentum (sentiment score 0.75), against the acknowledged macroeconomic uncertainties that influenced its decision to maintain guidance, and assess the timeline for achieving broader pharmacy coverage and its contribution to long-term profitability.